Nijmegen, the Netherlands – Aiosyn is proud to announce the first results of an independent clinical performance study conducted for its Aiosyn Mitosis Breast solution. This study was performed at Radboud University Medical Center...

NIJMEGEN, the Netherlands – Aiosyn, a pioneering pathology software company specializing in AI-powered solutions for kidney disease and breast cancer, has integrated its glomerular quantification algorithm with Sectra’s diagnostic...

From Aiosyn via Pathology News: What is chronic kidney disease (CKD)? Chronic kidney disease (CKD) is a progressive condition where the kidneys gradually lose function [1]. It is characterized by a high morbidity and mortality rate, and it is...

From the Aiosyn blog: After joining the team in 2022, Blazej has played a crucial role in developing and training Aiosyn’s products, particularly AiosynQC. In this interview, he shares insights on: Collaborating with pathologists to...

From the Aiosyn blog:  Throughout history, pathology has remained an integral component of medicine, tracing its origins to ancient healers recognizing the importance of understanding disease processes for effective treatments. What began...

Aiosyn, a medical software company specializing in AI-powered pathology solutions for cancer and kidney diseases, recently conducted a clinical performance study in collaboration with Radboud university medical center. This study evaluated the...